RNS Number : 7493E

Physiomics PLC

03 March 2020

3 March 2020

Physiomics Plc

("Physiomics") or (the "Company")

Interim Results Statement

for the six-month period ended 31 December 2019

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour(TM) technology to support the development of cancer treatment regimens and personalised medicine solutions, today announces its financial results for the six months ended 31 December 2019.

Summary financial results

   --        Revenue of GBP343k (six months ended 31 December 2018: GBP324k) 
   --        Total income of GBP343k (six months ended 31 December 2018: GBP372k*) 
   --        Operating loss of GBP118k (six months ended 31 December 2018: GBP113k) 
   --        Cash and cash equivalents of GBP434k at 31 December 2019 (31 December 2018: GBP552k) 
   --        Shareholders' funds of GBP532k at 31 December 2019 (31 December 2018: GBP639k) 

* Total income for the six months ended 31 December 2018 includes other operating income , being grant income , of GBP48k . No grant income is included in the six months ended 31 December 2019.

Operational highlights

Key events in the period include:

-- Agreement with Bicycle Therapeutics and CRUK to analyse clinical data from the first in man study of BT1718

-- Continued relationship with Merck KGaA for the provision of a range of modelling and simulation services during the course of 2020

-- Follow-on contract with CellCentric Ltd for pharmacokinetic/pharmacodynamic (PKPD) modelling in support of the clinical development of its lead clinical asset CCS1477

Key event after the period end:

-- Two further contracts of undisclosed value with existing client Bicycle Therapeutics have been announced today

Chairman and CEO's statement


Revenue in the first half was around 6% ahead of the comparable period in 2018, although total income was around 8% lower, as no grant income was received during the period. Despite this, operating losses were held steady at GBP118k, just GBP5k more than the previous period. Careful management of cash helped the Company to achieve a net cash inflow of GBP29k during the period, with the Company having cash and cash equivalents of GBP434k as at 31 December 2019 (30 June 2019: GBP405k). The second half revenues for the last two financial years have significantly exceeded those of the first half and the Board expects this trend to continue in the current financial year. Notably, in the last financial year, the majority of the Company's grant income was recognised in the first half whereas in the current financial year, any grant income received would start to be recognised in the second half (January to June 2020).

Business strategy update

The Company is very pleased to be attracting follow-on projects with a range of clients including CellCentric and Bicycle Therapeutics, as well as its long-term client Merck KGaA ("Merck"). These projects span a number of key approaches to cancer therapy, including immuno-oncology, radiotherapy and DNA damage/repair agents. In parallel with ensuring repeat business, the Company is highly focused on identifying new clients and, to this end, it has made, and will continue to make, significant investments in marketing, including:

   --        Attendance at key industry conferences; 

-- Additional external business development support to complement internal capabilities/capacity;

-- Digital marketing via targeted advertisements on the widely used business platform, LinkedIn;

-- Subscription to databases allowing the Company to track potential oncology clients as they attract funding and progress their programs to stages of development where we can support them; and

   --        Direct marketing telephone campaigns targeted at relevant potential clients. 

The Company is also in the final stages of securing a further grant in respect of its personalised oncology offering. A further announcement will be made in due course, as and when appropriate.


We are looking forward to a solid second half underpinned by significant contracted revenues from Merck, Bicycle Therapeutics and CellCentric, as well as other potential projects with existing and new clients.


Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

Notes to Editor

About Physiomics

Physiomics(R) is an oncology consultancy which uses mathematical PKPD models as well as its proprietary Virtual Tumour(TM) technology to predict the effects of cancer drugs and treatments and improve the success rate of drug discovery and development projects. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight. Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

For more information please visit:




 Physiomics Plc 
 Unaudited Statement of Comprehensive Income for the half year ended 31 December 2019 
                                                                 Unaudited            Unaudited       Audited 
                                                              Half year to         Half year to    Year ended 
                                                                 31-Dec-19            31-Dec-18     30-Jun-19 
                                                                   GBP'000              GBP'000       GBP'000 
 Revenue                                                               343                  324           719 
 Other operating income                                                  -                   48            64 
 Total income                                                          343                  372           783 
 Operating expenses before exceptional costs                         (461)                (485)         (984) 
 Operating loss and loss before taxation                             (118)                (113)         (201) 
 UK corporation tax                                                     36                   49            97 
 Loss for the period attributable to equity shareholders              (82)                 (64)         (104) 
                                                           ---------------      ---------------   ----------- 
 Loss per share (pence) 
   Basic and diluted       (0.11)   p   (0.09)   p   (0.14)   p 

Physiomics Plc

 Unaudited Statement of financial position as at 31 December 2019 
                                     Unaudited       Unaudited          Audited 
                                         As at           As at            As at 
                                     31-Dec-19       31-Dec-18        30-Jun-19 
                                       GBP'000         GBP'000          GBP'000 
 Non-current assets 
 Intangible assets                           4               -                1 
 Property, plant and equipment              14              19               19 
                                            18              19               20 
 Current assets 
 Trade and other receivables               152             269              269 
 Cash and cash equivalents                 434             552              405 
                                           586             821              674 
 Total assets                              604             840              694 
                                  ------------      ----------      ----------- 
 Current liabilities 
 Trade and other payables                 (72)            (61)             (85) 
 Deferred revenue                            -           (140)              (1) 
                                  ------------      ----------      ----------- 
 Total liabilities                        (72)           (201)             (86) 
                                  ------------      ----------      ----------- 
 Net assets                                532             639              608 
                                  ------------      ----------      ----------- 
 Capital and reserves 
 Share capital                           1,181           1,181            1,181 
 Capital reserves                        5,426           5,411            5,420 
 Profit & loss account                 (6,075)         (5,953)          (5,993) 
 Equity shareholders' funds                532             639              608 
                                  ------------      ----------      ----------- 
 Physiomics Plc 
 Unaudited Statement of changes in equity for the half year ended 31 December 2019 
                                                      Share      Share-based                       Total 
                                         Share      premium     compensation    Retained   shareholders' 
                                       capital      account          reserve    earnings           funds 
                                       GBP'000      GBP'000          GBP'000     GBP'000         GBP'000 
 At 1 July 2018                          1,181        5,228              170     (5,889)             690 
 Transfer to other reserves                  -            -               13           -              13 
 Loss for the period                         -            -                -        (64)            (64) 
 At 31 December 2018                     1,181        5,228              183     (5,953)             639 
 Transfer to other reserves                  -            -                9           -               9 
 Loss for the period                         -            -                -        (40)            (40) 
 At 30 June 2019                         1,181        5,228              192     (5,993)             608 
 Transfer to other reserves                  -            -                6           -               6 
 Loss for the period                         -            -                -        (82)            (82) 
 At 31 December 2019                     1,181        5,228              198     (6,075)             532 
 Physiomics Plc 
 Unaudited Cash Flow Statement for the half year ended 31 December 2019 
                                                               Unaudited       Unaudited       Audited 
                                                            Half year to    Half year to    Year ended 
                                                               31-Dec-19       31-Dec-18     30-Jun-19 
                                                                 GBP'000         GBP'000       GBP'000 
 Cash flows from operating activities: 
 Operating loss                                                    (118)           (113)         (201) 
 Amortisation and depreciation                                         5               3             8 
 Share-based compensation                                              7              13            22 
 (Increase) decrease in receivables                                   57            (30)          (13) 
 Increase / (decrease) in payables                                  (12)               5            25 
 Increase / (decrease) in deferred revenue                           (1)              72          (67) 
 Cash generated from operations                                     (62)            (50)         (226) 
 UK corporation tax received                                          95              47            82 
 Net cash generated from operating activities                         33             (3)         (144) 
 Cash flows from investing activities: 
 Purchase of non-current assets, net of grants received              (4)            (17)          (23) 
 Net cash used by investing activities                               (4)            (17)          (23) 
                                                           -------------   -------------   ----------- 
 Net (decrease) / increase in cash and cash equivalents               29            (20)         (167) 
 Cash and cash equivalents at beginning of period                    405             572           572 
 Cash and cash equivalents at end of period                          434             552           405 
                                                           -------------   -------------   ----------- 

Physiomics Plc

Notes to the Interim Financial Statements

   1.   General information 

Physiomics Plc is a public limited company ("the Company") incorporated in England & Wales (registration number 4225086). The Company is domiciled in the United Kingdom and its registered address is The Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA. The Company's ordinary shares are traded on the AIM Market of the London Stock Exchange ("AIM"). Copies of the interim report are available from the Company's website, www.physiomics-plc.com. Further copies of the Interim Report and Annual Report and Accounts may be obtained from the address above.

The Company's principal activity is the provision of services to pharmaceutical companies in the area of outsourced systems and computational biology.

   2.   Basis of preparation 

The interim financial statements of the Company for the six months ended 31 December 2019, which are unaudited, have been prepared in accordance with the accounting policies set out in the annual report and accounts for the year ended 30 June 2019, which were prepared under International Financial Reporting Standards ("IFRS").

The financial information contained in the interim report does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006. The financial information for the full preceding year is based on the statutory accounts for the year ended 30 June 2019. Those accounts, upon which the auditors, Shipleys LLP, issued a report which was unqualified but contained an emphasis of matter paragraph, have been delivered to the Registrar of Companies.

As permitted, this interim report has been prepared in accordance with the AIM Rules for Companies and not in accordance with IAS 34 "Interim Financial Reporting" therefore it is not fully compliant with IFRS.

The interim financial statements are presented in sterling and all values are rounded to the nearest thousand pounds (GBP'000) except when otherwise indicated.

   3.   Loss per share 

Basic loss per share is 0.11p (H1 2018: loss per share 0.09p). The basic loss per ordinary share is calculated by dividing the loss of GBP82,148 (H1 2018: loss GBP63,935) by 71,910,394 (H1 2018: 71,910,394), the weighted average number of shares in issue during the period.

The loss attributable to equity holders (holders of ordinary shares) of the Company for calculating the fully diluted loss per share is identical to that used for calculating the loss per share. The exercise of share options would have the effect of reducing the loss per share and is therefore anti- dilutive.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



(END) Dow Jones Newswires

March 03, 2020 02:01 ET (07:01 GMT)